Icon (NASDAQ:ICLR) Stock Rating Lowered by Rothschild & Co Redburn

Icon (NASDAQ:ICLR) was downgraded by Rothschild & Co Redburn from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. They presently have a $100.00 price target on the medical research company’s stock. Rothschild & Co Redburn’s price objective indicates a potential upside of 3.63% from the stock’s previous close.

ICLR has been the topic of several other reports. TD Cowen reiterated a “hold” rating on shares of Icon in a research note on Thursday, February 12th. Leerink Partners reissued a “market perform” rating and issued a $105.00 price objective on shares of Icon in a research note on Thursday, February 12th. UBS Group set a $220.00 target price on shares of Icon in a research note on Friday, October 24th. Bank of America reissued an “underperform” rating and set a $75.00 price target on shares of Icon in a report on Thursday, February 12th. Finally, Barclays lifted their price objective on Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Icon has a consensus rating of “Hold” and an average target price of $160.13.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $96.50 on Tuesday. Icon has a one year low of $66.57 and a one year high of $211.00. The stock has a market capitalization of $7.79 billion, a price-to-earnings ratio of 13.06, a PEG ratio of 2.15 and a beta of 1.27. The company has a 50-day simple moving average of $170.51 and a 200-day simple moving average of $173.20. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vident Advisory LLC lifted its stake in shares of Icon by 47.2% during the 4th quarter. Vident Advisory LLC now owns 41,059 shares of the medical research company’s stock worth $7,482,000 after purchasing an additional 13,175 shares during the period. NewEdge Advisors LLC increased its stake in Icon by 8.6% in the fourth quarter. NewEdge Advisors LLC now owns 1,309 shares of the medical research company’s stock valued at $238,000 after purchasing an additional 104 shares during the last quarter. Moore Capital Management LP boosted its stake in Icon by 96.7% in the 4th quarter. Moore Capital Management LP now owns 57,190 shares of the medical research company’s stock worth $10,421,000 after buying an additional 28,116 shares during the last quarter. Irenic Capital Management LP purchased a new stake in Icon in the 4th quarter valued at about $1,458,000. Finally, Janus Henderson Group PLC increased its stake in shares of Icon by 12.7% during the 4th quarter. Janus Henderson Group PLC now owns 248,279 shares of the medical research company’s stock valued at $45,241,000 after acquiring an additional 28,008 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: TD Cowen upgraded ICON after the recent selloff, citing valuation recovery potential and prompting buying interest. TD Cowen upgrades ICON ICON rises as Cowen upgrades
• Neutral Sentiment: ICON has delayed release of its Q4 and full‑year 2025 financial results while the accounting review continues; investors should await the company’s revised filings for clarity on the magnitude and timing of any restatements. PR Newswire: ICON faces investigation
• Negative Sentiment: Multiple law firms have launched securities‑fraud investigations alleging potential material misstatements after the internal probe — an escalation that increases litigation risk and potential costs. (Levi & Korsinsky, Bragar Eagel & Squire, Block & Leviton solicitations.) Levi & Korsinsky investigation Bragar Eagel & Squire investigation Block & Leviton investigation
• Negative Sentiment: An analyst downgrade at Rothschild & Co Redburn (buy→hold, $100 PT) reduces buy‑side endorsement and could cap near‑term upside despite the upgrade from Cowen. Rothschild & Co Redburn downgrade

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.